Characterizing genomic signatures in predicting renal cell carcinoma therapy response


To characterize genomic backgrounds of responders’ vs non-responders to current immunotherapies for renal cell carcinoma



Immunotherapy is the main stay of treatment for renal cell carcinoma. However, to date, clinicians cannot predict which patients may respond or be refractory to treatment. The aim of this project is to characterize genomic backgrounds and biomarkers that could infer response vs resistant to such therapies